TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33831327
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (200 micrograms, orally administered, 4 times daily for 8 weeks)
Study: 34271853
Drug: Hydromorphone hydrochloride
Normalized name: Hydromorphone Hydrochloride
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone hydrochloride 0.1 mg/kg (H1)
Study: 34271853
Drug: Hydromorphone hydrochloride
Normalized name: Hydromorphone Hydrochloride
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone hydrochloride 0.2 mg/kg (H2)
Study: 34271853
Drug: Sufentanil 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 1.5 µg/kg (S)
Study: 33099662
Drug: P. fluorescens
Approvals — FDA: no, EMA: no, PMDA: no
Description: P. fluorescens and P. indica (alone or in combination)
Study: 33099662
Drug: P. indica
Normalized name: Cannabis sativa subsp. indica top
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P. indica (alone or in combination with SPB)
Study: 32729888
Drug: Ranibizumab, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab, 0.5 mg every 4 weeks (arm A)
Study: 32729888
Drug: Faricimab, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faricimab, 1.5 mg every 4 weeks (arm B)
Study: 32729888
Drug: Faricimab, 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faricimab, 6.0 mg every 4 weeks (arm C)
Study: 32729888
Drug: Faricimab, 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faricimab, 6.0 mg every 4 weeks until week 12, then faricimab, 6.0 mg every 8 weeks (arm D)
Study: 32729888
Drug: Ranibizumab, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab, 0.5 mg every 4 weeks until week 8, then faricimab, 6.0 mg every 4 weeks (arm E)
Study: 33725857
Drug: Yiqi Liangxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Liangxue Shengji prescription (YLS)
Study: 33415555
Drug: Nebulized isotonic
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized isotonic magnesium (1024 mg/h)
Study: 33415555
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium (200 mg/kg over 30 min, followed by 50 mg/kg/h)
Study: 34530112
Drug: 30 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/d of 85% cocoa chocolate (DC85)
Study: 34635353
Drug: Copper and
Normalized name: Copper and/or copper compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper and zinc chelate gel (coppergel)
Study: 33840773
Drug: Varenicline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (up to 2 mg daily)
Study: 33999270
Drug: Dignity therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dignity therapy (N = 32)
Study: 39606414
Drug: mTOR inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: mTOR inhibitors
Study: 35550508
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance chemotherapy
Study: 32112496
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy (CBT) for 14 weeks
Study: 616625620
Drug: Ginseng extract
Normalized name: ginseng extract
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng extract (300 mg)
Study: 34412166
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg pure CBD
Study: 34412166
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg pure CBD
Study: 34412166
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg pure CBD
Study: 33745898
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical therapy (IMT) including high-intensity statins and ACE-I or ARB
Study: 33617367
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment condition (control)
Study: 36908150
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg pitavastatin
Study: 35732378
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment by IAPT therapists
Study: 39075156
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MT)
Study: 35808889
Drug: Intravenous propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propranolol
Study: 34838156
Drug: Dabrafenib 150
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg twice daily plus trametinib 2 mg once daily orally
Study: 32085669
Drug: Trastuzumab-based neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab-based neoadjuvant therapy
Study: 32085669
Drug: Trastuzumab-based neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab-based neoadjuvant therapy with ct-miR-148a and ct-miR-140-5p
Study: 33135865
Drug: Ertugliflozin/metformin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin/metformin FDC tablet (2.5/500 mg or 7.5/850 mg)
Study: 33135865
Drug: Canadian-sourced metformin
Normalized name: Canadian bluegrass pollen extract
DrugBank: Poa compressa pollen (DB10713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canadian-sourced metformin coadministered with ertugliflozin
Study: 34149587
Drug: Conventional Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Therapy (CT)
Study: 36333268
Drug: Osimertinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib (80 mg once daily) and Savolitinib (300 mg twice daily)
Study: 34767869
Drug: Deucravacitinib (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib (selective TYK2 inhibitor)
Study: 33887241
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (25 μg)
Study: 33887241
Drug: Slow-release dinoprostone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release dinoprostone pessary (10 μg)
Study: 33476803
Drug: Durvalumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (10 mg/kg, intravenous, every 2 weeks for ≤12 months)
Study: 32731478
Drug: Apple beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple beverage (234 mg flavanols)
Study: 32731478
Drug: Coffee berry
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee berry beverage (440 mg chlorogenic acid)
Study: 32731478
Drug: Blueberry beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry beverage (300 mg anthocyanins)
Study: 35692065
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone acetate group (n=28)
Study: 35692065
Drug: Combined with
Normalized name: Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined with local injection Triamcinolone acetonide group (n=30)
Study: 36065092
Drug: ZYIL1 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYIL1 (oral NLRP3 inflammasome inhibitor)
Study: 34220712
Drug: Ding-Kun Pill
Normalized name: Ding xiang
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ding-Kun Pill (DKP) 7g twice daily
Study: 34220712
Drug: Placebo 7g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 7g twice daily
Study: 32216911
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of neurohumoral blocker therapy
Study: 32216911
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of renin‐angiotensin‐aldosterone system inhibitors
Study: 32216911
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of beta‐blockers
Study: 32216911
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of renin‐angiotensin‐aldosterone system inhibitors and beta‐blockers
Study: 35751480
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A injection combined with finasteride and minoxidil
Study: 35751480
Drug: Control side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control side (no botulinum toxin A injection)
Study: 32531982
Drug: Prebiotic oligofructose-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic oligofructose-enriched inulin (10 g per day)
Study: 35889769
Drug: Nutraceutical combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical combination containing phytosterols, bergamot, olive fruits, and vitamin K2
Study: 36240610
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low fixed dose of GH (0.1 mg/day)
Study: 36240610
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of GH (initially 0.13 mg/day, increased to 0.31 mg/day)
Study: 38363950
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (CPT) alone
Study: 34275488
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of DMARDs
Study: 33469728
Drug: Intravenous GGS
Normalized name: Immunoglobulin, anti-(human death receptor 5) (human-Lama glama clone IF5 single-domain VHH fragment) fusion protein with peptide linker (GGS)2 fusion protein with immunoglobulin anti-(human death receptor 5) (human-Lama glama clone IF5 single-domain VHH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GGS (freeze‐dried sulfonated human normal immunoglobulin)
Study: 33469728
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (steroid pulse)
Study: 32400000
Drug: Estrogen Deprivation
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole
Study: 35450742
Drug: mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirabegron 50 mg once daily
Study: 35450742
Drug: solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: solifenacin 5 mg per day
Study: 35450742
Drug: combined solifenacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined solifenacin 5 mg and mirabegron 50 mg once daily
Study: 32872748
Drug: Gout patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gout patients receiving anti-gout medication
Study: 34739002
Drug: Early metabolic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early metabolic support (EMS) with peripheral amino acid infusions
Study: 34059363
Drug: Conventional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medication counselling method (CMC)
Study: 33107439
Drug: Dose Titration
Normalized name: Rebif Rebidose Titration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Titration (DT)
Study: 35793609
Drug: Na2SeO3 (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na2SeO3 (sodium selenite) continuous infusion at a pharmacological dose of 4 mg Se/day on day-1, followed by a high nutritional dose of 1 mg Se/day for 9 days
Study: 32103326
Drug: Decontamination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decontamination with polymyxin B, tobramycin, vancomycin, and amphotericin B, administered four times per day starting the day before surgery until postoperative day 7.
Study: 32103326
Drug: Placebo (amphotericin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (amphotericin B only), administered four times per day starting the day before surgery until postoperative day 7.
Study: 35776749
Drug: Data augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data augmentation approach
Study: 33129455
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration of toxic K. brevis (> 1 million cells L‐1) at normoxic levels (7.2 mg L‐1)
Study: 33129455
Drug: Moderate hypoxia
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hypoxia (1.5 mg L‐1) with high concentration of K. brevis
Study: 33129455
Drug: Severe hypoxia
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe hypoxia (0.63 mg L‐1) with high concentration of K. brevis
Study: 33129455
Drug: Normoxic control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoxic control (7.3 mg L‐1) with no K. brevis
Study: 33069888
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 plus carboplatin (AUC 5 mg/mL/min) with pembrolizumab 200 mg (up to 2 years)
Study: 33069888
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 plus carboplatin (AUC 5 mg/mL/min) without pembrolizumab (chemotherapy alone)
Study: 34034784
Drug: COVID-19 specific
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 specific monoclonal antibodies (mABs) authorized by the EUAs (bamlanivimab and etesevimab; casirivimab and imdevimab)
Study: 32162808
Drug: Sequential FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential FOLFIRI followed by Cisplatin and Docetaxel
Study: 32162808
Drug: Tumor PD-L1
Normalized name: HUMAN BREAST TUMOR CELL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor PD-L1 ≥ 1% in sequential chemotherapy
Study: 35627351
Drug: Core strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core strength training (CST) programme (n = 16) performed thrice weekly
Study: 33057670
Drug: treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment as usual with adjunctive psycho-social intervention for medication adherence
Study: 33057670
Drug: treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment as usual without adjunctive psycho-social intervention
Study: 32150017
Drug: Single-session treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-session treatment group (26 patients)
Study: 32150017
Drug: Weekly management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly management group (27 patients)
Study: 35351871
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity counselling intervention (introductory behavioural coaching session followed by eight weekly follow-up sessions)
Study: 37640025
Drug: treatment
Normalized name: Acne Treatment
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment
Study: 34343108
Drug: Metformin (1000–2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000–2000 mg daily for 3 months)
Study: 34343108
Drug: Insulin (non-MET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (non-MET group)
Study: 35917806
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin 40 IU
Study: 34861827
Drug: CRAFT written
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRAFT written material as a supplement
Study: 33831623
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no inhaled salbutamol)
Study: 33824226
Drug: Choir intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Choir intervention (2-hr ensemble singing + 1-hr home vocal training weekly)
Study: 33824226
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (listened to a 3-hr playlist weekly, attended concerts, and socialized online)
Study: 32302064
Drug: Calcium glucoheptonate
Normalized name: Calcium glucoheptonate
DrugBank: Calcium glucoheptonate (DB00326)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium glucoheptonate (250 mg/10 mL, two oral ampoules)
Study: 32302064
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (500 mg elemental calcium, one effervescent tablet)
Study: 34326053
Drug: Identification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identification of open bile ducts with administration of 20-40 mL SMOFlipid5% in the bile tract
Study: 34518246
Drug: Friendship Bench
Normalized name: beach strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Friendship Bench (FB) intervention, details on dosage and duration not specified.
Study: 34518246
Drug: Cluster randomised
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster randomised controlled trial of the optimised Friendship Bench intervention, details on dosage and duration not specified.
Study: 35062944
Drug: Established non-invasive
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established non-invasive ventilation (NIV) treatment
Study: 34570177
Drug: Levetiracetam, 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam, 125 mg, twice daily for 4 weeks
Study: 32205751
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of botulinum toxin (8U)
Study: 32205751
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of botulinum toxin
Study: 33323473
Drug: Steering immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steering immunosuppressive therapy by levels of virus-specific T cells
Study: 33323473
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with trough-level monitoring of immunosuppressants
Study: 34515737
Drug: CONNECT intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CONNECT intervention (3 monthly visits with trained oncology nurses)
Study: 37336058
Drug: IC14 (anti-CD14
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC14 (anti-CD14 monoclonal antibody)
Study: 38431043
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus immunotherapy
Study: 34326209
Drug: Nicotinamide mononucleotide
Normalized name: NICOTINAMIDE MONONUCLEOTIDE
DrugBank: Nicotinamide Mononucleotide (DB03227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide mononucleotide (NMN) therapy
Study: 35535503
Drug: mRNA-1273 vaccine
Normalized name: SARS-CoV-2 mRNA-1273 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 vaccine (100 µg)
Study: 34876434
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg ATG
Study: 38059944
Drug: Supportive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Therapy (ST)
Study: 34387740
Drug: N-acetyl-L-leucine (NALL)
Normalized name: N-acetyl-l-leucine
DrugBank: L-Acetylleucine (DB16956)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-L-leucine (NALL) 4 g/day for patients ≥ 13 years, weight-tiered doses for patients 6-12 years
Study: 34387740
Drug: N-acetyl-L-leucine (NALL)
Normalized name: N-acetyl-l-leucine
DrugBank: L-Acetylleucine (DB16956)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-L-leucine (NALL)
Study: 35517892
Drug: Melatonin (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (21 mg/day)
Study: 32297703
Drug: Intrarenal artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarenal artery infusion of autologous peripheral-blood-derived CD34+ cells (2.5 × 10^7 cells for each intrarenal artery)
Study: 32297703
Drug: Standardized pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized pharmacotherapy only (control group)
Study: 32297703
Drug: Intrarenal artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarenal artery infusion of autologous peripheral-blood-derived CD34+ cells
Study: 36457297
Drug: Crisis Counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisis Counseling (CC)
Study: 32367870
Drug: 600 μg
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 μg oral misoprostol
Study: 34559113
Drug: Chuna Manual
Normalized name: China-Gel
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chuna Manual Therapy (CMT) administered once a week for 8 weeks
Study: 34559113
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug treatment (Control)
Study: 37723577
Drug: Upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 15 mg QD
Study: 38923871
Drug: Upadacitinib 30
Normalized name: upadacitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 30 mg QD
Study: 34968730
Drug: Dose-escalated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated group (upadacitinib 30 mg QD)
Study: 39287491
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy
Study: 35738801
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICIs) treatment for uHCC
Study: 33829647
Drug: Enoxaparin followed
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin followed by a vitamin K antagonist
Study: 34042412
Drug: Short-wave diathermy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-wave diathermy (SWD) treatment
Study: 33104028
Drug: Multi-Component Cognitive
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-Component Cognitive Stimulation Therapy (SADEM)